Epochal sales record of Hanmi's Amodipin.

Published: 2006-09-11 06:58:00

Updated: 2006-09-11 06:58:00

Just in 2 years of its market launching of Amodipin developed by Hanmi as a modified new amlodipine derivative, it made an epochal record with the total 8.5 million prescriptions, the aggregated sales and the NHI financial saving at the total 30 billion won up to September this year.

Currently...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK